This trial is evaluating whether Treatment will improve 1 primary outcome and 10 secondary outcomes in patients with Neoplasms, Lung. Measurement will happen over the course of From time of enrollment through last contact (6 months)/date of death, whichever came first.
This trial requires 42 total participants across 0 different treatment group
"Lung cancer is relatively rare compared to other cancers; however, the mortality is high. It remains unclear how great the risk of death from lung cancer is relative to other cancers. Current evidence suggests that most people diagnosed with lung cancer will die within five years, although some fail to respond to chemotherapy. This implies that the average survival time from diagnosis to death is around one year." - Anonymous Online Contributor
"Results from a recent paper of our study do not support the claim that cigarette smoking causes lung cancer. In fact, we found that the risk of developing lung cancer was lower among smokers than non-smokers. We conclude that cigarette smoking is unlikely to be a major factor in the development of lung cancer in North Carolina." - Anonymous Online Contributor
"Recent findings suggest that a multimodality approach may be associated with improved survival compared with a standard approach for advanced nonsmall cell lung cancer. However, larger prospective studies are needed to confirm these findings." - Anonymous Online Contributor
"While there is strong evidence from epidemiological studies that smoking affects lung cancer risk substantially, we find no precedent from epidemiological studies to suggest a "hereditary" model of lung cancer susceptibility. In fact, the familial clustering observed in a recent study is even stronger than any observed in the general population, reinforcing the lack of support for an "hereditary" model of lung cancer susceptibility." - Anonymous Online Contributor
"The incidence rate of lung cancer seems higher in men than women. The most common age group for lung cancer in India is between 50-59 years old. The lifetime risk of developing lung cancer is 1%. Host factors such as smoking, exposure to asbestos and environmental factors such as passive smoke and air pollution are associated with lung cancer development." - Anonymous Online Contributor
"Current therapies provide undefined benefit to patients with advanced lung cancer. Physicians should be cautious about prescribing palliative care for their patients with advanced lung cancer." - Anonymous Online Contributor
"Patients undergoing chemotherapy experienced fatigue, nausea, vomiting, diarrhea, constipation, anemia, neutropenia, thrombocytopenia, leukopenia, fever, and rash; they had no changes in triglycerides or cholesterol levels or hepatic toxicity. Patients undergoing RT had gastrointestinal problems, leukopenia, thrombocytopenia, and congestion. There were no changes in triglycerides or cholesterol levels or hepatic toxicity. Patients receiving EGFR TKIs experienced fatigue, constipation, nausea, vomiting, diarrhea, dizziness, insomnia, peripheral edema, dyspnea, and weakness." - Anonymous Online Contributor
"Typically, surgical resection is combined with adjuvant chemotherapy for lung cancer. For patients with primary non-small cell lung carcinoma, adjuvant chemotherapy improves survival compared to surgery alone." - Anonymous Online Contributor
"The cure rate varies widely across institutions. Some patients may benefit from additional therapy while others may not need further treatment after surgery and/or chemotherapy. The timing of intervention should be tailored to each patient's specific clinical presentation." - Anonymous Online Contributor
"There's a huge variation in lung cancer incidence rates across the country. For example, the annual lung cancer incidence rate was 1.9 per 100,000 person-years in New Jersey and 10.5 in Florida. As such, it seems important to examine trends in lung cancer incidence across the US in order to better understand geographic disparities in lung cancer mortality. Although the data are limited in their scope, they suggest that higher socioeconomic status may be associated with increased lung cancer incidence. However, because no clear trend emerged, further studies will be required to confirm these findings." - Anonymous Online Contributor
"People who receive concurrent chemotherapy and anti-angiogenic treatment had an increased risk of toxicity compared with those receiving only anti-angiogenic therapy. Treatment should therefore be carefully considered before starting a new anticancer treatment regimen in patients with metastatic disease who are already receiving anti-angiogenic therapy." - Anonymous Online Contributor